GlassScriptPhysician profile
Scott Eric Morningstar
NPI 1174122790
$3,125.40
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $1,355 · 2023: $883 · 2024: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,117.73 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $540.22 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $198.22 | 2022-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $164.82 | 2021-2024 | |
| Nevro Corp. | $138.98 | 2022 | |
| Medtronic, INC. | $103.16 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $97.11 | 2023 | Rexulti |
| Amgen INC. | $92.20 | 2021-2023 | Otezla, Repatha |
| Lilly USA, LLC | $90.68 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $83.59 | 2022-2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $58.78 | 2022 | |
| Xeris Pharmaceuticals, INC. | $48.12 | 2021-2022 | |
| Abbvie INC. | $40.44 | 2022-2023 | |
| Shield Therapeutics INC | $39.75 | 2023-2024 | Accrufer |
| Pfizer INC. | $38.53 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $33.01 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $27.96 | 2023-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.59 | 2024 | Jardiance |
| Exact Sciences Corporation | $24.94 | 2023 | Cologuard Collection Kit |
| Abiomed | $23.99 | 2023 | Impella |
| Amarin Pharma, INC. | $19.25 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.81 | 2024 | Voquezna |
| Dexcom, INC. | $18.70 | 2022 | |
| Lundbeck LLC | $18.70 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $17.18 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.27 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $15.57 | 2022 | |
| Radius Health, INC. | $13.10 | 2023 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Morningstar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.